Identification of cytochrome P450 3A1/2 as the major P450 isoform responsible for the metabolism of fentanyl by rat liver microsomes

Anesthesia and Analgesia

Volumn 82, Issue 5, 1996, Pages 936-941

  Feierman, Dennis E ^a,b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLPYRAZOLE; ALCOHOL; BENZOFLAVONE DERIVATIVE; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; ERYTHROMYCIN; FENTANYL; IMMUNOGLOBULIN G; KETOCONAZOLE; NORFENTANYL; PHENOBARBITAL; QUINIDINE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEALKYLATION; DRUG METABOLISM; DRUG OXIDATION; ENZYME ANALYSIS; GAS CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0029985906     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199605000-00008     Document Type: Article

References (22)

1. Lehmann KA, Moseler G, Daub D. Biotransformation von Fentanyl. I. In vitro abbau durch gewebe der Maus. Anaesthesist 1981;30:461-6.
2. Lehmann KA, Weski C, Hunger L, et al. Biotransformation von Fentanyl. II. Akute Arzneimittelinteraktioen- Untersuchungen bei Ratte und Mensch. Anaesthesist 1982;31:221-7.
3. Lehmann KA, Hunger L, Brandt K, Daub D. Biotransformation von Fentanyl. III. Einflusse chronischer arzneimittelexposition auf verteilung, metabolismus und Ausscheidung bei der Ratte. Anaesthesist 1983;32:165-73.
4. Haberer JP, Schoeffler P, Couderc E, Duvaldesrin P. Pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth 1982;54:1267-70.
5. Van Wijngaarden I, Soudijn W. The metabolism and excretion of the analgesic fentanyl (R 4263) by Wistar Rats. Life Sci 1968;7: 1239-44.
6. Van Rooy HH, Vermeulen NPE. The assay of fentanyl and its metabolites in the plasma of patients using gas chromatography with alkali flame ionization detection and gas chromatographymass spectrometry. J Chromatogr 1981;223:85-93.
7. Goromaru T, Matsuura H, Yoshimura N, et al. Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography-mass spectrometry. Anesthesiology 1984;61:73-7.
8. Maruyama Y, Hosoya E. Studies on the fate of fentanyl. Keio J Med 1969;18:59-70.
9. Meuldermans W, Hendrickx J, Lauwers W, et al. Excretion and biotransformation of alfentanil and sufentanil in rats and dogs. Drug Metab Dispos 1987;15:905-13.
10. Lavrijsen K, Van Houdt J, Van Dyck D, et al. Biotransformation of sufentanil in liver microsome of rats, dogs and humans. Drug Metab Dispos 1990;18:704-10.
11. Kharasch ED, Thummel KE. Human alfentanil metabolism by cytochrome P450 3A3/4, an explanation for the interindividual variability in alfentanil clearance. Anesth Analg 1993;76:1033-9.
12. Yun C, Wood M, Wood AJJ, Guengerich EP. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance. Anesthesiology 1992;77:467-74.
13. Feierman DE, Cederbaum AI. Oxidation of the alcohol dehydrogenase inhibitor pyrazole to 4-hydroxypyrazole by microsomes. Drug Metab Dispos 1987;15:634-9.
14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193: 265-75.
15. Omura T, Sato R. The carbon-monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964;239:2370-8.
16. Silverstein JH, Rieders MF, McMullin M, et al. An analysis of the duration of fentanyl and its metabolites in urine and saliva. Anesth Analg 1993;76:618-21.
17. Gonzalez FJ, Schmid BJ, Umeno M, et al. Human P450PCN1: sequence, chromosomal location, and direct evidence through cDNA expression that P450CN1 is nifedipine oxidase. DNA 1988;7:79-86.
18. Feierman DE, Cederbaum AI. Increased sensitivity of the microsomal oxidation of ethanol to inhibition by pyrazole and 4-methylpyrazole after chronic ethanol treatment. Biochem Pharmacol 1987;36:3277-83.
19. Newton DJ, Wang R, Lu AYH. Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995;23:154-8.
20. Bartkowski RR, Goldberg ME, Larijani GE, Boerner T. Inhibition of alfentanil metabolism by erythromycin. Clin Pharmacol Ther 1989;46:99-102.
21. Hiller A, Olkkola KT, Isohanni P, Saarnivaara I. Unconsciousness associated with midazolam and erythromycin. Br J Anaesth 1990;65:826-8.
22. Potter JM, Balderson GA, Hickman PB, et al. The value of the donor MEGX test in predicting liver allograft recipient outcome. Transplantation 1994;58:524-6.